Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4306 - Tumor Treating Fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: Phase 3 INNOVATE-3/ENGOT-ov50 study


29 Sep 2019


Poster Display session 2


Tumour Site

Ovarian Cancer


Ignace Vergote


Annals of Oncology (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250


I.B. Vergote1, L. Copeland2, B.J. Monk3, R.L. Coleman4, D. Cibula5, J. Sehouli6, E.P. Samartzis7, M. Radoslaw8, A. González Martín9, J. Korach10, V. Salutari11, P.O. Witteveen12, D. O’Malley13

Author affiliations

  • 1 Gynaecology, Belgian Gynecologic Oncology Group (BGOG) and University of Leuven, 3000 - Leuven/BE
  • 2 Gynecologic Oncology, Ohio State University Comprehensive Cancer Center, Hilliard, OH 43026 - Hilliard/US
  • 3 Medical Oncology, University of Arizona Cancer Center, 85724-5024 - Tucson/US
  • 4 Gynecologic Oncology And Reproductive Medicine, The M. D. Anderson Cancer Center, 77030-3721 - Houston/US
  • 5 First Faculty Of Medicine, Charles University and General University Hospital, Prague/CZ
  • 6 Gynecology, Universitätsklinik Charité, Campus Virchow Klinikum, 13353 - Berlin/DE
  • 7 Klinik Für Gynäkologie, Universitätsspital Zürich, Zurich/CH
  • 8 Oddział Ginekologii Onkologicznej Katedry I Kliniki Onkologii, Uniwersytet Medyczny im K. Marcinkowskiego w Poznaniu, Poznań/PL
  • 9 Medical Oncology Department, Clínica Universidad de Navarra, 28036 - Madrid/ES
  • 10 Josef Buchmann Gynecology And Maternity Center, Chaim Sheba Medical Center, 5265601 - Ramat Gan/IL
  • 11 Gynecology Oncology Unit, Policlinico Universitario Agostino Gemelli, Rome/IT
  • 12 Medical Oncology, University Medical Center Utrecht Cancer Center, Utrecht/NL
  • 13 Gynecologic Oncology, Ohio State University Comprehensive Cancer Center, 43026 - Hilliard/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4306


Tumour Treating Fields (TTFields) are a non-invasive, regional antimitotic therapy. In preclinical models of ovarian cancer, TTFields (200 kHz) reduced cell viability and showed synergistic effects with taxanes in vitro and in vivo. The Phase 2 INNOVATE study [NCT02244502] demonstrated safety of TTFields plus weekly paclitaxel in 31 PROC (platinum-resistant ovarian cancer) patients (Vergote et al Gyn Onc 2018;150:471). No increase in grade 3–4 TTFields were reported; 26 patients (84%) had TTFields-related dermatitis; one patient permanently discontinued TTFields due to dermatitis. Patients received median of 4 prior therapies; 100% prior platinum and 97% prior taxanes. Median PFS was 8.9 months, 25% had partial response and clinical benefit rate was 71%. The median overall survival was not reached: the one-year survival rate was 61%. This phase 3 INNOVATE-3/ENGOT-ov50 study [NCT03940196] investigates TTFields combined with weekly paclitaxel in PROC patients.

Trial design

Patients (N = 540) will have disease progression (PROC per RECIST V1.1) within 6 months of last platinum therapy with a maximum of 2-5 prior lines of systemic therapy, ECOG score of 0-1 and no peripheral neuropathy above grade1. Patients with primary refractory disease (progression during first line therapy) will be excluded. Patients will be randomized 1:1 to either weekly paclitaxel alone or weekly paclitaxel plus TTFields (200 kHz). Weekly paclitaxel will be administered at standard starting of dose 80 mg/m2 weekly for 8 weeks, and then on Days 1, 8, and 15 for subsequent 28-day cycle. TTFields will be delivered for 18 hours/day and continued if no progression in the abdominal or pelvic regions (“in-field region”) per RECIST V1.1. Clinical follow up will be performed q4w, with radiological follow up (CT or MRI scans of the abdomen and chest) q8w. The primary endpoint is overall survival. Main secondary endpoints: progression-free survival, objective response rate, severity and frequency of AEs, and quality of life (EORTC QLQ-C30 with QLQ-OV28). Sample size (n = 540) will detect an increase in median overall survival from 12 to 16 months (Hazard ratio 0.75).

Clinical trial identification

ENGOT/ov50; NCT03940196.

Editorial acknowledgement

Legal entity responsible for the study





I.B. Vergote: Advisory / Consultancy: Roche NV, Genmab A/S, Advaxis Inc., Morphotek Inc., F. Hoffmann-La Roche Ltd.; Research grant / Funding (institution): Amgen and Roche; Advisory / Consultancy: Cerculean Pharma Inc., Novocure GmBh, AstraZeneca,; Advisory / Consultancy: Mateon Therapeutics Inc., Immunogen; Advisory / Consultancy: Eli Lilly Benelux NV, Amgen Inc., Theradex Europe; Advisory / Consultancy: Pfizer Inc., Debiopharma International SA, Vifor Pharma België; Advisory / Consultancy: Novartis Pharma AG, MSD Belgium BVBA, Janssen-Cilag; Advisory / Consultancy: Bayer Pharma AG, Clovis Oncology, Takeda, Pharma Mar, Oncoinvent; Travel / Accommodation / Expenses: Tesaro, Clovis Oncology, Takeda,; Travel / Accommodation / Expenses: Pharma Mar, Roche, Genmab and Oncoinvent. D. Cibula: Advisory / Consultancy: Roche, AstraZeneca, Sotio. V. Salutari: Honoraria (self) / Advisory role / Speaker Bureau: Roche, AstraZeneca, Tesaro, PharmaMar, MSD, Clovis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.